The Relative Strength (RS) Rating for Eli Lilly moved into a new percentile Friday, as it got a lift from 68 to 72.
This exclusive rating from Investor's Business Daily identifies share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks typically have an 80 or higher RS Rating as they begin their biggest climbs. See if Eli Lilly can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
Eli Lilly is working on a cup with handle with a 935.63 buy point. See if the stock can clear the breakout price in heavy volume.
Earnings growth slowed last quarter from 1,080% to 114%. But revenue gains moved higher, from 20% to 45%.
Eli Lilly earns the No. 2 rank among its peers in the Medical-Diversified industry group. AstraZeneca ADR is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
